Organization | Petrov Research Institute of Oncology

Petrov Research Institute of Oncology Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Saint Petersburg Russian Federation (1927)

Organization Overview

First Clinical Trial

2013

NCT01883518

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Research Institute of Oncology named after N.N. Petrov

Active Ingredients

Drugs in Phase 3 Trials (5)

inosine (1 trial)

methionine (1 trial)

nicotinamide (1 trial)

ringer's lactate (1 trial)

sodium succinate (1 trial)

Drugs in Phase 2 Trials (8)

cyclophosphamide (cytoxan) (1 trial)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (1 trial)

fluorouracil (efudex) (1 trial)

melatonin (3 trials)

sitagliptin (januvia) (3 trials)

toremifene (fareston) (1 trial)

tumor-pulsed dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Jaundice (Phase 3)

Jaundice, Obstructive (Phase 3)

Melanoma (Phase 2)

Neoplasms, Connective and Soft Tissue (Phase 2)

Sarcoma (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 13